Find Upadacitinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1310726-60-3, Abt-494, Rinvoq, Upadacitinib anhydrous, 4ra0kn46e0, (3s,4r)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
Molecular Formula
C17H19F3N6O
Molecular Weight
380.4  g/mol
InChI Key
WYQFJHHDOKWSHR-MNOVXSKESA-N
FDA UNII
4RA0KN46E0

Upadacitinib
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.
1 2D Structure

Upadacitinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
2.1.2 InChI
InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
2.1.3 InChI Key
WYQFJHHDOKWSHR-MNOVXSKESA-N
2.1.4 Canonical SMILES
CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
2.1.5 Isomeric SMILES
CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
4RA0KN46E0
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide

2. Abt-494

3. Rinvoq

2.3.2 Depositor-Supplied Synonyms

1. 1310726-60-3

2. Abt-494

3. Rinvoq

4. Upadacitinib Anhydrous

5. 4ra0kn46e0

6. (3s,4r)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

7. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide

8. (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

9. 1-pyrrolidinecarboxamide, 3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)-, (3s,4r)-

10. Mfcd30502663

11. Upadacitinib [usan]

12. Upadacitinib [mi]

13. Upadacitinib, Abt-494

14. Upadacitinib (usan/inn)

15. Upadacitinib [inn]

16. Upadacitinib [usan:inn]

17. Upadacitinib (abt-494)

18. Unii-4ra0kn46e0

19. Upadacitinib [who-dd]

20. Gtpl9246

21. Schembl9991056

22. Chembl3622821

23. Abt 494

24. Dtxsid901027919

25. Upadacitinib [orange Book]

26. Amy16528

27. Bcp19011

28. Ex-a1628

29. Bdbm50503287

30. S8162

31. Cs-6150

32. Db15091

33. Abbv-599 Component Upadacitinib

34. Abt494;abt-494;abt 494

35. Ncgc00588874-01

36. Ac-30326

37. As-56379

38. Hy-19569

39. Upadacitinib Component Of Abbv-599

40. J3.590.729g

41. C72237

42. D10994

43. Q27074125

44. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin- 8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Tyrosine Kinase Inhibitor

45. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2- Trifluoroethyl)pyrrolidine-1-carboxamide

46. Rel-(-)-(3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

2.4 Create Date
2012-08-19
3 Chemical and Physical Properties
Molecular Weight 380.4 g/mol
Molecular Formula C17H19F3N6O
XLogP32.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count3
Exact Mass380.15724374 g/mol
Monoisotopic Mass380.15724374 g/mol
Topological Polar Surface Area78.3 Ų
Heavy Atom Count27
Formal Charge0
Complexity561
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Upadacitinib is indicated for the treatment of moderately to severely active rheumatoid arthritis or active psoriatic arthritis in adult patients who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate or TNF blockers. For these indications, upadacitinib may be used as monotherapy or in combination with methotrexate. Upadacitinib is also indicated for the treatment of active ankylosing spondylitis in adult patients who have an inadequate response to conventional therapy and for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Combining upadacitinib with other JAK inhibitors, biologic DMARDs, or other potent immunosuppressive agents is not recommended.


FDA Label


Rheumatoid arthritis

RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis

RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA)

RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis )

RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Atopic dermatitis

RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis

RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.


Treatment of ulcerative colitis


Treatment of Crohn's disease


Treatment of vasculitides


Treatment of vasculitides


Treatment of atopic dermatitis


Treatment of chronic idiopathic arthritis (including rheumatoid arthritis , psoriatic arthritis , spondyloarthritis and juvenile idiopathic arthritis )


5 Pharmacology and Biochemistry
5.1 Pharmacology

Upadacitinib is a DMARD that works by inhibiting the Janus Kinases (JAKs), which are essential downstream cell signalling mediators of pro-inflammatory cytokines. It is believed that these pro-inflammatory cytokines play a role in many autoimmune inflammatory conditions, such as rheumatoid arthritis. In clinical trials, upadacitinib decreased the activity of pro-inflammatory interleukins, transiently increased the levels of lymphocytes, and insignificantly decreased the levels of immunoglobulins from the baseline.


5.2 MeSH Pharmacological Classification

Antirheumatic Agents

Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)


Janus Kinase Inhibitors

Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)


5.3 ATC Code

L04AA


L - Antineoplastic and immunomodulating agents

L04 - Immunosuppressants

L04A - Immunosuppressants

L04AA - Selective immunosuppressants

L04AA44 - Upadacitinib


5.4 Absorption, Distribution and Excretion

Absorption

Upadacitinib displays a dose-proportional pharmacokinetic profile over the therapeutic dose range. Following oral administration, the median time to reach Cmax (Tmax) ranges from 2 to 4 hours. The steady-state plasma concentrations of upadacitinib are reached within 4 days following multiple once-daily administrations, with minimal accumulation. Food intake has no clinically relevant effect on the AUC, Cmax, and Cmin of upadacitinib from the extended-release formulation.


Route of Elimination

Following administration of a single radio-labelled dose from the immediate-release formulation, approximately 53% of the total dose was excreted in the feces where 38% of the excreted dose was an unchanged parent drug. About 43% of the total dose was excreted in the urine, where 24% of that dose was in the unchanged parent drug form. Approximately 34% of the total dose of upadacitinib dose was excreted as metabolites.


Volume of Distribution

The volume of distribution of upadacitinib in a patient with rheumatoid arthritis and a body weight of 74 kg is estimated to be 224 L following oral administration of an extended-release formula. In a pharmacokinetic study consisting of healthy volunteers receiving the extended-release formulation, the steady-state volume of distribution was 294 L. Upadacitinib partitions similarly between plasma and blood cellular components with a blood to plasma ratio of 1.0.


Clearance

The apparent oral clearance of upadacitinib in healthy volunteers receiving the extended-release formulation was 53.7 L/h.


5.5 Metabolism/Metabolites

Upadacitinib predominantly undergoes CYP3A4-mediated metabolism; however, upadacitinib is a nonsensitive substrate of CYP3A4. It is also metabolized by CYP2D6 to a lesser extent. In a human radio-labelled study, about 79% of the total plasma radioactivity accounted for the parent drug, and about 13% of the total plasma radioactivity accounted for the main metabolite produced from mono-oxidation, followed by glucuronidation. There are no known active metabolites of upadacitinib.


5.6 Biological Half-Life

The mean terminal elimination half-life of upadacitinib ranged from 8 to 14 hours following administration of the extended-release formulation. In clinical trials, approximately 90% of upadacitinib in the systemic circulation was eliminated within 24 hours of dosing.


5.7 Mechanism of Action

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that involves the interplay of several mediators, including the immune cells (mainly T- and B-lymphocytes) and pro-inflammatory cytokines, such as the tumour necrosis factor (TNF), transforming growth factor (TGF), and interleukin 6 (IL-6). The Janus Kinase (JAK) family plays an essential role in the normal physiological functions (such as erythropoiesis), but also the signalling of pro-inflammatory cytokines that are implicated in many immune-mediated diseases. The JAK family consists of four isoforms (JAK1, JAK2, JAK3, and Tyrosine Kinase 2) that each interacts with different cytokine receptors and uniquely associates with the intracellular domains of Type I/II cytokine receptors. JAK1 is primarily involved in the signalling transduction pathways of IL-6, IFN and the common -chain cytokines, including IL-2 and IL-15. IL-6 has been closely studied in particular, as it is a major cytokine involved in B- and T-cell differentiation and the acute phase response in inflammation. Upon interaction of cytokines with their cytokine receptors, the JAKs mediate the JAK-STAT signal transduction pathway in response to receptor activation. JAKs are tyrosine kinases that cause phosphorylation of several proteins, including cytokine receptors and JAKs themselves. Phosphorylation of JAKs promotes the phosphorylation and activation of the signalling molecules called STATs, leading to their nuclear translocation, binding to DNA promoters, and target gene transcription. JAK1-mediated signalling pathways ultimately promote pro-inflammatory events, such as increased proliferation and survival of immune cells, T cell differentiation, and macrophage activation. Upadacitinib is a selective JAK1 inhibitor that has a negligible effect on JAK3, leading to an improved drug safety profile. Upadacitinib blocks the cellular processes that contribute to the inflammatory conditions in rheumatoid arthritis. In human leukocytes cellular assays, upadacitinib inhibited JAK1/3-induced phosphorylation of STAT3/5 mediated by IL-6/7.


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39979

Submission : 2024-07-30

Status : Active

Type : II

Metrochem

02

Pharmex
Not Confirmed

02

Pharmex
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-04-24

Pay. Date : 2023-02-21

DMF Number : 38095

Submission : 2023-02-22

Status : Active

Type : II

blank

03

Pharmex
Not Confirmed

04

Pharmex
Not Confirmed

05

Curia Spain Sau

U.S.A

USDMF

arrow
Pharmex
Not Confirmed

05

Pharmex
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-08-16

Pay. Date : 2022-06-15

DMF Number : 37149

Submission : 2022-06-01

Status : Active

Type : II

blank

06

Lee Pharma Ltd

India

USDMF

arrow
Pharmex
Not Confirmed

06

Pharmex
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39581

Submission : 2024-03-12

Status : Active

Type : II

blank

07

Pharmex
Not Confirmed

07

Pharmex
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-07-17

Pay. Date : 2023-04-25

DMF Number : 38153

Submission : 2023-03-26

Status : Active

Type : II

blank

08

Pharmex
Not Confirmed

09

Pharmex
Not Confirmed

10

Hoster Labs Private Ltd

Country

USDMF

arrow
Pharmex
Not Confirmed

10

Hoster Labs Private Ltd

Country
arrow
Pharmex
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-07-05

Pay. Date : 2023-05-15

DMF Number : 38344

Submission : 2023-05-20

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.

Flag China
Digital Content Digital Content

Upadacitinib

About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...

Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming to global API standards, along with professional R&D and marketing teams, Hengkang’s operations span major pharmaceutical markets such as China, Europe, the CIS region, Japan, and South Korea. Hengkang has established long-term and stable relationships with nearly 70 countries overseas and hundreds of domestic enterprises.
Zhejiang Hengkang Pharmaceutical

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

Flag India
Digital Content Digital Content

Upadacitinib

About the Company : Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical com...

Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical company in 1995. Today, we have 11,000 employees and are heading towards a turnover of INR 50000 million. Our vast network includes 50 C&F agents and 7500+ stockists. We provide a wide range of products – Antibiotic, Antifungal, NSAIDs, Gastrointestinal, Anthelmintic, Cardiovascular, Dermal, Erectile Dysfunction, and several other categories – across the nation.
Company Banner

03

Honour Lab

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

Upadacitinib

About the Company : Honour is a leading global CDMO and specialty chemicals & ingredients manufacturer with seven facilities set to global standards of safety and quality. With our offerings, Honour S...

Honour is a leading global CDMO and specialty chemicals & ingredients manufacturer with seven facilities set to global standards of safety and quality. With our offerings, Honour Synthesis and Honour Specialty, we embrace the science of partnership and possibilities. Our 2500+ team delivers excellence to our pharmaceutical and biotechnology partners through practical solutions. Our commitment to transforming everyday life expands to specialty ingredients for electronics and pharma. Upholding top Environmental, Social, and Governance standards, we collaborate with stakeholders for sustainable, people-centric, transformative outcomes.
Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Upadacitinib

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.
Transo Pharm USA Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Upadacitinib

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Flag Hungary
Digital Content Digital Content

Upadacitinib

About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...

Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.
Egis Pharmaceuticals

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.

Flag China
Digital Content Digital Content

Upadacitinib

About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has ...

Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has 6 workshops and 9 production lines which has 100t/month production capacity.The company is committed to maintain the standards with continuous improvements to the current standards throughout the product lifecycle.The main products include local anesthetic drugs, antiviral drugs, cardiovascular and cerebrovascular drugs, antitumor drugs, gastrointestinal drugs, diabetic drugs, veterinary drugs, and CDMO products.
Shandong Chenghui Shuangda Pharmaceutical

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content

Upadacitinib

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
Jinan Tantu Chemicals

09

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Upadacitinib

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...

Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development Zone, Shandong Province, Shandong Loncom has operational API pilot tests and production bases adhering to international standards. With 13 production lines dedicated to oral solid preparations, oral liquid preparations and API, it is actively expanding its preparation workshops for small-volume injections, soft capsules, eye drops, topical medicines and innovative drug R&D centres.
Shandong Loncom Pharmaceutical company banner

10

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Upadacitinib

About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
Shanghai Minbiotech CB
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667154600,"product":"UPADACITINIB HEMIHYDRATE","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TESTAPLAST RAW MATERIALS TRADING LL","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.70","actualQuantity":"700","unit":"GMS","unitRateFc":"80","totalValueFC":"54178.1","currency":"EURO","unitRateINR":6368.5714285714284,"date":"31-Oct-2022","totalValueINR":"4458000","totalValueInUsd":"54178.1","indian_port":"BOMBAY AIR","hs_no":"29349100","bill_no":"5145562","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698345000,"product":"UPADACITINIB HEMIHYDRATE IN-HOUSE PHARMACEUTICAL FOR PHARMACEUTICAL RAW MATERIALAS PER PO","address":"PLOT NO.131,3RD FLOOR,NARMADA","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"UNDISCLOSED","customerCountry":"EGYPT","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"40000","totalValueFC":"59330.1","currency":"USD","unitRateINR":3292000,"date":"27-Oct-2023","totalValueINR":"4938000","totalValueInUsd":"59330.1","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"4923286","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADA, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702319400,"product":"UPADACITINIB HEMIHYDRATE IHS PHARMACEUTICAL RAW MATERIALS METROCHEM BATCH NO: ULS-P\/23001","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"SUNGWOO CHEMICAL CO LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.04","actualQuantity":"0.04","unit":"KGS","unitRateFc":"150000","totalValueFC":"5850.3","currency":"USD","unitRateINR":12175000,"date":"12-Dec-2023","totalValueINR":"487000","totalValueInUsd":"5850.3","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"5983939","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704393000,"product":"UPADACITINIB HEMIHYDRATE IHS PHARMACEUTICAL RAW MATERIALS METROCHEM BATCH NO: ULS-P\/23001","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"HANSOL PHARMA CO LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"63000","totalValueFC":"6201.7","currency":"USD","unitRateINR":5154346.6999999993,"date":"05-Jan-2024","totalValueINR":"515434.67","totalValueInUsd":"6201.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6530048","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713983400,"product":"UPADACITINIB HEMIHYDRATE","address":"PLOT NO.131,3RD FLOOR,NARMADA","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"KING PRIME GLOBAL PROCUREMENT","customerCountry":"UNITED ARAB EMIRATES","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"68325","totalValueFC":"215143.6","currency":"EURO","unitRateINR":5988686.25,"date":"25-Apr-2024","totalValueINR":"17966058.75","totalValueInUsd":"215143.6","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"9396879","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADA, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714156200,"product":"UPADACITINIB (EXPORT INVOICE NO:6124010019 DT:23.04.2024)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"MASUNG LS CO LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"86","totalValueFC":"16942.8","currency":"USD","unitRateINR":7074.2550000000001,"date":"27-Apr-2024","totalValueINR":"1414851","totalValueInUsd":"16942.8","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"9448606","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714674600,"product":"UPADACITINIB","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"MPEAK KOREA COLTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"106000","totalValueFC":"10444.8","currency":"USD","unitRateINR":8706184.3000000007,"date":"03-May-2024","totalValueINR":"870618.43","totalValueInUsd":"10444.8","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"9596370","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717093800,"product":"UPADACITINIB (EXPORT INVOICE NO:6124010094 DT:29.05.2024)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA LTD","supplierCountry":"INDIA","foreign_port":"MUSCAT","customer":"SMART SUPPLY INTERNATIONAL LLC","customerCountry":"OMAN","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"80000","totalValueFC":"21438.6","currency":"EURO","unitRateINR":7148000,"date":"31-May-2024","totalValueINR":"1787000","totalValueInUsd":"21438.6","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"1315956","productDescription":"API","marketType":"","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729103400,"product":"UPADACITINIB","address":"HOSTER LABS PRIVATE LIMITED","city":"HYDERABAD","supplier":"HOSTER LABS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"AMSTERDAM, SCHIPHOL","customer":"CYBERFREIGHT BV C O MEDICA PHARMA","customerCountry":"NETHERLANDS","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"100","totalValueFC":"971","currency":"USD","unitRateINR":8158.8000000000002,"date":"17-Oct-2024","totalValueINR":"81588","totalValueInUsd":"971","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4878558","productDescription":"API","marketType":"REGULATED MARKET","country":"NETHERLANDS","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HOSTER LABS PRIVATE LIMITED, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741717800,"product":"UPADACITINIB HEMIHYDRATE, CAS # 2050057-56-0, BATCH # ANT-UPC-001, ORGANIC CHEMICAL REF. STANDARD 200 MG X 05 VIALS","address":"GODBOLE BAUG, VADAYALI","city":"AMBERNATH [E], DIST-THANE[INDIA]","supplier":"ANANT LABORATORIES","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"HIKMA SPECIALIZED PHARMACEUTICALS","customerCountry":"EGYPT","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"435","totalValueFC":"389.2","currency":"USD","unitRateINR":33708.150000000001,"date":"12-Mar-2025","totalValueINR":"33708.15","totalValueInUsd":"389.2","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"8926539","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"GODBOLE BAUG, VADAYALI, AMBERNATH [E], DIST-THANE[INDIA]","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645122600,"product":"UPADACITINIB","address":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,","city":"HYDERABAD,TELANGANA","supplier":"HANGZHOU PROSERRE CHEMICAL CO LTD","supplierCountry":"CHINA","foreign_port":"NA","customer":"NATCO PHARMA LTD","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"68000","totalValueFC":"34495.8","currency":"USD","unitRateINR":"5171400","date":"18-Feb-2022","totalValueINR":"2585700","totalValueInUsd":"34495.8","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"7552454","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"NATCO HOUSE, ROAD NO.2,,BANJARA H ILLS,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647887400,"product":"UPADACITINIB (FOR R &D PURPOSE)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"CURIA SPAIN SAU","supplierCountry":"SPAIN","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"1.10","actualQuantity":"1.1","unit":"KGS","unitRateFc":"150000","totalValueFC":"166473.1","currency":"USD","unitRateINR":"11535000","date":"22-Mar-2022","totalValueINR":"12688500","totalValueInUsd":"166473.1","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7958202","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648665000,"product":"UPADACITINIB, BATCH NO. V2994\/0 21060, TL NO. TL\/NZ\/21\/000393, 1 X 0.400 KG","address":"SPARC TANDALJA","city":"VADODARA","supplier":"CURIA SPAIN SAU","supplierCountry":"SPAIN","foreign_port":"NA","customer":"SUN PHARMACEUTICAL INDUSTRIES LTD","customerCountry":"INDIA","quantity":"0.40","actualQuantity":"0.4","unit":"KGS","unitRateFc":"125000","totalValueFC":"50446.4","currency":"USD","unitRateINR":"9612500","date":"31-Mar-2022","totalValueINR":"3845000","totalValueInUsd":"50446.4","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"8087620","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SPARC TANDALJA"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653589800,"product":"UPADACITINIB","address":"SPARC TANDALJA","city":"VADODARA","supplier":"CURIA SPAIN SAU","supplierCountry":"SPAIN","foreign_port":"NA","customer":"SUN PHARMACEUTICAL INDUSTRIES LTD","customerCountry":"INDIA","quantity":"4.40","actualQuantity":"4.4","unit":"KGS","unitRateFc":"85000","totalValueFC":"380360","currency":"USD","unitRateINR":"6681000","date":"27-May-2022","totalValueINR":"29396400","totalValueInUsd":"380360","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"8863406","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SPARC TANDALJA"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659292200,"product":"UPADACITINIB (FOR R & D PURPOSE)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"CURIA SPAIN SAU","supplierCountry":"SPAIN","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"0.61","actualQuantity":"0.612","unit":"KGS","unitRateFc":"125000","totalValueFC":"77829.5","currency":"USD","unitRateINR":"10118750","date":"01-Aug-2022","totalValueINR":"6192675","totalValueInUsd":"77829.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9814111","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659292200,"product":"UPADACITINIB (FOR R & D PURPOSE)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"CURIA SPAIN SAU","supplierCountry":"SPAIN","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"125000","totalValueFC":"127172.5","currency":"USD","unitRateINR":"10118750","date":"01-Aug-2022","totalValueINR":"10118750","totalValueInUsd":"127172.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9814111","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663957800,"product":"UPADACITINIB - BATCH NO - V2994\/0 22070","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"CURIA SPAIN SAU","supplierCountry":"SPAIN","foreign_port":"NA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"106000","totalValueFC":"212685","currency":"USD","unitRateINR":"8522400","date":"24-Sep-2022","totalValueINR":"17044800","totalValueInUsd":"212685","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2597250","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668105000,"product":"UPADACITINIB (BATCH NO.: V2994\/0 22120)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,,","city":"AHMEDABAD,GUJARAT","supplier":"CURIA SPAINSAU","supplierCountry":"SPAIN","foreign_port":"N\/A","customer":"INTAS PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"83866.7","totalValueFC":"1291716.2","currency":"USD","unitRateINR":"7028026.7","date":"11-Nov-2022","totalValueINR":"105420400","totalValueInUsd":"1291716.2","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29339990","bill_no":"1004680","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"N\/A","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701714600,"product":"LUT-7 ACTIVE PHARMACEUTICALS INGREDIENTS (UPADACITINIB) (CASNUMBER 1310726-60-3 BATCH V2994\/0 22171)","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"CURIA SPAIN SAU","supplierCountry":"SPAIN","foreign_port":"MADRID","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"0.025","unit":"KGS","unitRateFc":"104000","totalValueFC":"2897.9","currency":"EURO","unitRateINR":"9649347.6","date":"05-Dec-2023","totalValueINR":"241233.69","totalValueInUsd":"2897.9","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"9082299","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRID","supplierAddress":"PARQUE TECHNOLOGICO DE BOECILLOPARCELA 105 47151 BOECILLOVALLADOLID SPAIN","customerAddress":"SANDOZ HOUSE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715538600,"product":"UPADACITINIB-VALUE FOR CUSTOM PURPOSES ONLY","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"","supplier":"ER SQUIBB SONSLLC","supplierCountry":"UNITED STATES","foreign_port":"N\/A","customer":"SYNGENE INTERNATIONAL LTD UNIT II BLOCK S 11","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"1000","totalValueFC":"5059.7","currency":"USD","unitRateINR":"84350","date":"13-May-2024","totalValueINR":"421750","totalValueInUsd":"5059.7","indian_port":"Biocon-SEZ","hs_no":"29339990","bill_no":"1005868","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"N\/A","customerAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3"}]
18-Feb-2022
12-Mar-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1310726-60-3 / Upadacitinib API manufacturers, exporters & distributors?

Upadacitinib manufacturers, exporters & distributors 1

75

PharmaCompass offers a list of Upadacitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Upadacitinib manufacturer or Upadacitinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Upadacitinib manufacturer or Upadacitinib supplier.

PharmaCompass also assists you with knowing the Upadacitinib API Price utilized in the formulation of products. Upadacitinib API Price is not always fixed or binding as the Upadacitinib Price is obtained through a variety of data sources. The Upadacitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Upadacitinib

Synonyms

1310726-60-3, Abt-494, Rinvoq, Upadacitinib anhydrous, 4ra0kn46e0, (3s,4r)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

Cas Number

1310726-60-3

Unique Ingredient Identifier (UNII)

4RA0KN46E0

About Upadacitinib

Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.

Upadacitinib Manufacturers

A Upadacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Upadacitinib, including repackagers and relabelers. The FDA regulates Upadacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Upadacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Upadacitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Upadacitinib Suppliers

A Upadacitinib supplier is an individual or a company that provides Upadacitinib active pharmaceutical ingredient (API) or Upadacitinib finished formulations upon request. The Upadacitinib suppliers may include Upadacitinib API manufacturers, exporters, distributors and traders.

click here to find a list of Upadacitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Upadacitinib USDMF

A Upadacitinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Upadacitinib active pharmaceutical ingredient (API) in detail. Different forms of Upadacitinib DMFs exist exist since differing nations have different regulations, such as Upadacitinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Upadacitinib DMF submitted to regulatory agencies in the US is known as a USDMF. Upadacitinib USDMF includes data on Upadacitinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Upadacitinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Upadacitinib suppliers with USDMF on PharmaCompass.

Upadacitinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Upadacitinib Drug Master File in Korea (Upadacitinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Upadacitinib. The MFDS reviews the Upadacitinib KDMF as part of the drug registration process and uses the information provided in the Upadacitinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Upadacitinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Upadacitinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Upadacitinib suppliers with KDMF on PharmaCompass.

Upadacitinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Upadacitinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Upadacitinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Upadacitinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Upadacitinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Upadacitinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Upadacitinib suppliers with NDC on PharmaCompass.

Upadacitinib GMP

Upadacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Upadacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Upadacitinib GMP manufacturer or Upadacitinib GMP API supplier for your needs.

Upadacitinib CoA

A Upadacitinib CoA (Certificate of Analysis) is a formal document that attests to Upadacitinib's compliance with Upadacitinib specifications and serves as a tool for batch-level quality control.

Upadacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Upadacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Upadacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Upadacitinib EP), Upadacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Upadacitinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty